cyclacel pharmaceuticals – cell cycle inhibitor study in solid and blood cancers
Published 1 year ago • 102 plays • Length 10:26Download video MP4
Download video MP3
Similar videos
-
8:26
cyclacel pharmaceuticals - cancer cell biology
-
17:10
sclc: therapeutic progress or mirage?
-
2:41
cell avidity as a predictor of t-cell efficacy
-
13:27
cell cycle and cancer - richard pestell
-
1:30
which cancer drugs are cell cycle-specific?
-
1:17
targeting persisting stem cells in search for a novel cml treatment
-
10:02
cyclins and cdks in the regulation of the cell cycle [retinoblastoma, c-myc, p53 and cdk inhibitors]
-
32:11
cell cycle cancer biology, chemotherapy, cml, and familial syndromes, [molecular biology 9 of 11]
-
0:50
treatment outcomes from primary ctcl
-
3:25
ash sickle cell disease initiative: policy and advocacy
-
1:51
generation of clinically compliant hesc/rpe cells for cell therapy of eye diseases
-
3:59
current therapeutic management strategies in sickle cell disease
-
4:25
the prognostic value of quantitative analysis of ccl5 and collagen iv – video abstract [id 159585]
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
3:01
cell-intrinsic biomarkers in cll: focus on cytogenetics
-
1:39
research that sheds light on the mechanism of action of pml in triple negative breast cancer
-
2:29
the measurement of molecular biomarkers to aid cll treatment
-
2:49
leukemic cell birth rate & the role of recently divided b cells in cll
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml